Solstice Neurosciences, Inc. Patent applications |
Patent application number | Title | Published |
20100112006 | Compositions of activated botulinum holotoxin type B (150 kD) - The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 99% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. | 05-06-2010 |
20100112005 | Compositions of activated botulinum toxin type B - The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of overactive or neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. | 05-06-2010 |
20100034854 | Compositions of activated botulinum holotoxin type B (150 KD) - The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 75% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention also relates to a process of stripping botulinum toxin type B, comprising the stages of: cell growth, activation, purification, and dilution; wherein at least one dissociating reagent is administered to a volume of said botulinum toxin type B; and wherein said dissociating reagent administered increases the levels of stripped botulinum toxin type B to at least 75%. | 02-11-2010 |
20100034853 | Compositions of activated botulinum toxin type B - The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked. | 02-11-2010 |